Drug Type Small molecule drug |
Synonyms 5(R)-5-hydroxytriptolide, 5-Hydroxytriptolide, Hydroxytriptolide + [7] |
Target |
Mechanism NOS2 inhibitors(Nitric oxide synthase, inducible inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC20H24O7 |
InChIKeyOKRSVUYYCJPECG-LFGMFVMYSA-N |
CAS Registry583028-68-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 2 | CN | 22 Jun 2020 | |
Rheumatoid Arthritis | Phase 2 | CN | 22 Jun 2020 | |
Acquired Immunodeficiency Syndrome | Phase 2 | CN | 25 Dec 2019 |
Phase 2 | 149 | cwekxqbupl(blmmoyfijx) = TEAEs were reported in 41 of 46 (89.1%) participants in HT8 group, 43 of 51 (84.3%) in LT8, and 42 of 52 (80.7%) in PL group eotbqnvnzf (utvszefdhd ) View more | Positive | 01 May 2023 | |||